FORMA Therapeutics, Inc.
500 Arsenal Street
Suite 100
Watertown
Massachusetts
02472
United States
Tel: 617-679-1970
Website: http://www.formatherapeutics.com/
Email: info@formatherapeutics.com
131 articles about FORMA Therapeutics, Inc.
-
FORMA Therapeutics Announces Upcoming Presentations at the 31st Annual Piper Jaffray Healthcare Conference and the 2019 ASH Annual Meeting
12/3/2019
FORMA Therapeutics Inc., a clinical stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced that the company will present at two meetings in December
-
FORMA Therapeutics’ Olutasidenib Demonstrates Positive Phase 1b/2 Results, including Blood-Brain Barrier Penetration and Stable Disease in Patients with IDH1-mutated Glioma
11/21/2019
FORMA Therapeutics, Inc., a clinical stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced positive Phase 1b/2 results from an ongoing study in patients with IDH1-mutated gliomas.
-
FORMA’s FASN Inhibitor FT-4101 Significantly Reduced Hepatic De Novo Lipogenesis in Healthy Adult Subjects
11/8/2019
FORMA Therapeutics, Inc., a clinical stage biopharmaceutical company focused on hematologic, oncologic and metabolic diseases, today announced the presentation of Phase 1 data for FT-4101, the company’s potent, selective fatty acid synthase (FASN) inhibitor in clinical development for the treatment of nonalcoholic steatohepatitis (NASH), at The Liver Meeting® 2019, the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD),
-
FORMA Announces Oral and Poster Presentations at Upcoming 2019 ASH Annual Meeting
11/6/2019
FORMA Therapeutics, Inc., a clinical stage biopharmaceutical company focused on rare hematological diseases and cancers, today announced that three abstracts have been accepted for presentation at the 61st American Society of Hematology (ASH) Annual Meeting being held in Orlando, Florida from December 7-10, 2019.
-
FORMA Therapeutics to Present Data for FASN Inhibitor FT-4101 at The Liver Meeting® 2019
10/1/2019
FORMA Therapeutics, Inc. today announced that new data related to FT-4101, its novel, small molecule fatty acid synthase (FASN) inhibitor, in clinical development for the treatment of nonalcoholic steatohepatitis (NASH), will be presented at The Liver Meeting® 2019, the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) taking place November 8-12, 2019 in Boston, MA.
-
BioSpace Movers & Shakers, Sept. 27
9/27/2019
Biotech and pharma companies strengthen their leadership teams and boards of directors with this week's appointments. -
FORMA Therapeutics Announces New Executive Leadership to Execute Next Phase of Growth for Company
9/24/2019
The Company also announced the appointments of Scott Boyle, Ph.D. as Vice President, Business and Corporate Development and Brian Lesser as Vice President, Therapeutic Head.
-
FORMA Therapeutics Announces Data for IDH1m Inhibitor Olutasidenib in Glioma to Be Presented at the 2019 Society for NeuroOncology Annual Meeting
9/11/2019
Data to highlight the penetration of olutasidenib across the blood brain barrier and preliminary safety and clinical activity from an ongoing Phase 1b/2 study
-
BioSpace Movers and Shakers: March 22
3/22/2019
Biotech and pharma companies make appointments to strengthen executive teams, with moves at Sanofi, Forma, Orchard, CLSA, Sangamo, and more. -
FORMA Therapeutics Announces Frank D. Lee as Chief Executive Officer
3/21/2019
FORMA Therapeutics announced today the appointment of Frank D. Lee as Chief Executive Officer, starting on March 27, 2019.
-
According to WARN notices, the two companies will slash a total of 106 jobs starting in March.
-
FORMA Therapeutics and HitGen Initiate Multiyear Research Collaboration
5/31/2018
FORMA expands external discovery research footprint with dedicated unit at HitGen
-
FORMA Therapeutics Announces Presentation at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
5/10/2018
FT-2102 IDH1m Inhibitor Clinical Data Selected for Oral Presentation
-
FORMA Therapeutics and the University of Oxford Announce Multi-Year Collaboration to Advance the Development of Deubiquitinating Enzyme (DUB) Inhibitors for the Treatment of Neurodegenerative Diseases
5/9/2018
FORMA expands translational footprint in Neurodegeneration with ARUK Oxford Drug Discovery Institute
-
Tim Clackson, Ph.D., Named to FORMA Therapeutics Board of Directors
4/9/2018
FORMA Therapeutics (FORMA) today announced the appointment of Tim Clackson, Ph.D., former President, Research and Development, ARIAD Pharmaceuticals, Inc. to the company’s Board of Directors.
-
FORMA Therapeutics Achieves Key Objective in Collaboration with Celgene Corporation to Advance a Novel Protein Homeostasis Oncology/Immuno-Oncology Program
4/5/2018
his collaboration enables Celgene to evaluate select therapeutic candidates and programs in protein homeostasis during preclinical development.
-
FORMA Therapeutics Appoints Frances Duffy-Warren, Ph.D., to Head of Regulatory Affairs
3/28/2018
Frances brings more than 30 years of pharmaceutical and regulatory experience, having previously worked for several global and emerging pharmaceutical companies.
-
FORMA Therapeutics Collaborates with Arpeggio Biosciences to Explore Translational Utility of Drug Candidates
3/26/2018
Arpeggio Biosciences will use its proprietary technology to identify immediate biological and genetic changes promoted by specific drug-target interactions
-
FORMA Therapeutics Appoints Christine Bellon, Ph.D., J.D., General Counsel and Corporate Secretary
11/14/2017
Chris joins the executive leadership team of FORMA with over 20 years of global experience in legal strategy, corporate partnerships and intellectual property, within the public and private Life Sciences sectors.
-
Celgene Throws Another $195 Million at FORMA To Keep The R&D Pact Going
8/29/2017